In order to find long-term, sustainable solutions to global health challenges, we need to engage in constructive discussions and be transparent about our views. We engage in policy debates and share the company’s perspective on issues including access to healthcare, ethics, R&D and quality of medicines, striving for open and constructive interaction.
As part of our ongoing commitment to transparency, we state our position on key issues affecting our business and of specific interest to our stakeholders.
As part of our ongoing commitment to transparency, we state our position on key issues affecting our business and of specific interest to our stakeholders.
- Animal research (PDF 0.2 MB)
- Clinical study transparency (PDF 0.2 MB)
- Medicines for Patients with Rare Diseases (PDF 0.2 MB)
- Post-trial Access (PDF 0.1 MB)
- Pre-Approval Access to Novartis Products through MAPs (PDF 0.3 MB)
- Responsible Clinical Trials (PDF 0.1 MB)
- Novartis Commitment to Diversity in Clinical Trials (PDF 0.2 MB)
- Novartis Position on Investigator Initiated Trials (IITs) and Investigator Initiated Research (IIRs) (PDF 0.2 MB)